Submit Manuscript  

Article Details


Honokiol: A Novel Natural Agent for Cancer Prevention and Therapy

[ Vol. 12 , Issue. 10 ]

Author(s):

S. Arora, S. Singh, G.A. Piazza, C.M. Contreras, J. Panyam and A.P. Singh   Pages 1244 - 1252 ( 9 )

Abstract:


Honokiol (3’,5-di-(2-propenyl)-1,1’-biphenyl-2,4’-diol) is a bioactive natural product derived from Magnolia spp. Recent studies have demonstrated anti-inflammatory, anti-angiogenic, anti-oxidative and anticancer properties of honokiol in vitro and in preclinical models. Honokiol targets multiple signaling pathways including nuclear factor kappa B (NF-κB), signal transducers and activator of transcription 3 (STAT3), epidermal growth factor receptor (EGFR) and mammalian target of rapamycin (m-TOR), which have great relevance during cancer initiation and progression. Furthermore, pharmacokinetic profile of honokiol has revealed a desirable spectrum of bioavailability after intravenous administration in animal models, thus making it a suitable agent for clinical trials. In this review, we discuss recent data describing the molecular targets of honokiol and its anti-cancer activities against various malignancies in pre-clinical models. Evaluation of honokiol in clinical trials will be the next step towards its possible human applications.

Keywords:

Honokiol, chemoprevention, chemotherapy, natural agent, Magnolia, traditional Chinese medicine, cancer, aspirin, taxol, natural products, anti-tumor activity, carcinoma, cytotoxicity, human myelogenous leukemia, adenocarcinoma

Affiliation:

Department of Oncologic Sciences, Mitchell Cancer Institute, University of South Alabama, 1660 Springhill Avenue, Mobile, AL 36604-1405, USA.



Read Full-Text article